Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer: Enhancing clinical relevance  

作　　者：Umashri Sundararaju Hamrish Kumar Rajakumar 

机构地区：[1]Department of General Surgery,Government Medical College,Omandurar Government Estate,Chennai 600002,Tamil Nadu,India

出　　处：《World Journal of Gastrointestinal Oncology》2025年第4期545-548,共4页世界胃肠肿瘤学杂志(英文)

摘　　要：Gastric cancer(GC)is a leading cause of cancer-related deaths,highlighting the need for reliable prognostic biomarkers to guide treatment.Wei et al’s systematic review and meta-analysis evaluates the neutrophil-to-lymphocyte ratio(NLR)as a potential biomarker for GC patients undergoing neoadjuvant chemotherapy.NLR is a simple and cost-effective measure of systemic inflammation that shows promise in predicting treatment response and survival outcomes,including overall survival and progression-free survival.However,variations in NLR thresholds and timing of measurements affect its accuracy and clinical utility.Moreover,the studies reviewed primarily involved Asian populations,which may limit the generalizability of the findings.To improve NLR’s clinical relevance,future research should focus on standardizing NLR thresholds,refining measurement timing,and incorporating additional inflammatory markers like platelet-to-lymphocyte ratio and Glasgow prognostic score.Addressing con-founders and including diverse patient populations will help improve NLR’s reliability as a prognostic marker for GC.

关 键 词：Gastric cancer Inflammatory markers Neoadjuvant chemotherapy Neutrophil-to-lymphocyte ratio Prognostic biomarker Survival outcomes 

分 类 号：R73[医药卫生—肿瘤]